MEDI0457 was subsequently studied in combination with the PD-L1 inhibitor durvalumab in a Phase Ib/IIa trial, including 29 evaluable patients with previously treated HPV-associated HNSCC who were immunotherapy-naïve. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.